|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product sales, net | |||||
| Collaborative and other research and development | |||||
| License and other revenues | |||||
| Total revenues | |||||
| Expenses: | |||||
| Cost of product sales | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Royalty | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Interest and other income | |||||
| Interest expense | |||||
| Other income (expense): | |||||
| Interest income | |||||
| Interest expense | |||||
| Foreign currency losses, net | |||||
| Loss on extinguishment of debt | |||||
| Other income | |||||
| Total other expense, net | |||||
| Income (loss) before income taxes | |||||
| Income tax expense | |||||
| Net income (loss) | |||||
| Other comprehensive income (loss): | |||||
| Foreign currency translation adjustment | |||||
| Unrealized (loss) gain on available for sale investments | |||||
| Total other comprehensive (loss) income | |||||
| Total other comprehensive (loss) income | |||||
| Net comprehensive income (loss) | |||||
| Net income (loss) per common share: basic (in usd per share) | |||||
| Weighted average shares of common stock outstanding: basic (in shares) | |||||
| Net income (loss) per common share: diluted (in usd per share) | |||||
| Weighted average shares of common stock outstanding: diluted (in shares) | |||||
Loading...